title: Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
abstract: OBJECTIVE
  Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma.
  
  
  METHODS
  Eleven patients with NGS testing were selected, with a total of 236 somatic cancer-related mutations analyzed. Descriptive and Kaplan-Meier statistics were applied.
  
  
  RESULTS
  The median age was 65 years (range=27-73 years); 4 (36%) patients were females. Seven (64%) and four patients (36%) had pleural and peritoneal mesothelioma, respectively. Detectable mutations were found in 86% of the pleural and 50% of the peritoneal mesothelioma patients (overall, 73% of patients). The families of BAP1 (36%), CDKNA2A/B (27%) and NF2 (27%) represented the most frequently mutated genes. The median overall survival for all patients was 20.8 months, with 1- and 2-year survival rates of 91% and 40%, respectively.
  
  
  CONCLUSIONS
  Genomic alterations as potential therapeutic targets were found by NGS. These findings will help in the development of new screening tools and targeting therapies, and in turn impact the standard-of-care and potentially lengthen disease control and survival periods in the future.
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, U.S.A. Department of Radiation Oncology, Acibadem Adana Hospital, Acibadem University, Adana, Turkey gamze.ugurluer@acibadem.edu.tr.
authors.forename: Gamze
authors.initials: G
authors.lastname: Ugurluer
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, U.S.A.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Chang
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
authors.forename: Mauricio E
authors.initials: ME
authors.lastname: Gamez
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, U.S.A.
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Arnett
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, U.S.A.
authors.forename: Ritujith
authors.initials: R
authors.lastname: Jayakrishnan
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, U.S.A. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, U.S.A.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Miller
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
authors.forename: Terence T
authors.initials: TT
authors.lastname: Sio
mesh_terms: D000328:Adult; D000368:Aged; D001195:Asbestosis / Q000150:complications; D004252:DNA Mutational Analysis / Q000379:methods*; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D052138:Genes, Neoplasm; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality; D008223:Lymphoma / Q000235:genetics; D008297:Male; D008654:Mesothelioma / Q000235:genetics* / Q000401:mortality; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D009381:Neoplasms, Radiation-Induced / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000235:genetics; D010534:Peritoneal Neoplasms / Q000235:genetics* / Q000401:mortality; D010997:Pleural Neoplasms / Q000235:genetics* / Q000401:mortality; D017422:Sequence Analysis, DNA
chemical_list: D004273:DNA, Neoplasm; D009363:Neoplasm Proteins
keywords: BAP1; CDKNA2A/B; Malignant mesothelioma; NF2; molecular targeting therapy; next-generation sequencing